Clinical Trials Logo

Filter by:
NCT ID: NCT00487526 Recruiting - Diabetes Mellitus Clinical Trials

Duodenal Jejunal Bypass for Type 2 Diabetes (DJBD)

DJBD
Start date: June 2007
Phase: Phase 1
Study type: Interventional

Study the effect of Duodenal jejunal bypass on human adults with type 2 diabetes.

NCT ID: NCT00426660 Completed - Clinical trials for Advanced HIV Infection

Expanded Access Program for Maraviroc At Multiple Centers

Start date: February 2007
Phase: Phase 3
Study type: Interventional

To provide access to maraviroc to patients who have limited or no therapeutic treatment options and to collect more safety data in a broader patient population.

NCT ID: NCT00414661 Completed - Clinical trials for Arthritis, Rheumatoid

Long-Term Safety Follow-Up Of Subjects Previously Enrolled In Rheumatoid Arthritis Studies Of CP-690,550

Start date: April 2007
Phase: N/A
Study type: Observational

The purpose of this study is to follow the health of subjects who have previously been enrolled in studies of CP-690,550 for treatment of their rheumatoid arthritis. Subjects are only eligible for this study after they have completed all participation in other studies of CP-690,550.

NCT ID: NCT00413699 Completed - Clinical trials for Arthritis, Rheumatoid

Long-Term Effectiveness And Safety Of CP-690,550 For The Treatment Of Rheumatoid Arthritis

Start date: February 5, 2007
Phase: Phase 3
Study type: Interventional

The purpose of this study is to determine the long-term effectiveness and safety of CP-690,550 for the treatment of rheumatoid arthritis. Subjects are eligible for this study only after participating in another "qualifying" study of CP-690,550 A sub-study will be conducted within the A3921024 study, this study will evaluate the immune response to pneumococcal and influenza vaccines in patients receiving CP-690,550

NCT ID: NCT00407537 Completed - Hypertension Clinical Trials

Caduet vs Usual Care in Subjects With Hypertension and Additional Risk Factors

CRUCIAL
Start date: March 2007
Phase: Phase 4
Study type: Interventional

To investigate whether a Caduet based treatment strategy might result in greater reduction in total cardiovascular risk as compared to usual care in subjects with hypertension and additional risk factors.

NCT ID: NCT00396630 Completed - Clinical trials for Infections, Rotavirus

A Study to Explore the Existence of Horizontal Transmission of the RIX4414 Vaccine Strain Between Twins Within a Family.

Start date: January 23, 2007
Phase: Phase 3
Study type: Interventional

The aim of this study is to explore horizontal transmission of the HRV (Human Rotavirus) vaccine strain within a family from the twin vaccinated with Rotarix to the twin receiving placebo. The Protocol Posting has been updated in order to comply with the FDA Amendment Act, Sep 2007.

NCT ID: NCT00386542 Completed - Influenza Clinical Trials

Needle-free Jet Injection of Reduced-dose, Intradermal, Influenza Vaccine in >= 6 to < 24-month-old Children

Start date: October 2006
Phase: Phase 1/Phase 2
Study type: Interventional

This is a sequential phase I and II, controlled, double-blinded study to determine whether immune responses suggesting protection against influenza can safely be induced in young children by two reduced doses one month apart of 0.1 mL of a trivalent inactivated influenza vaccine (INF) administered by the intradermal (ID) route with an investigational ID spacer on a United States (U.S.)-licensed needle-free jet injector (JI), compared to two standard intramuscular (IM) 0.25 mL doses by needle-syringe (N-S) in this age group. The locale is a developing country where financial restraints for the use of full-dose influenza vaccine would limit protection from an influenza pandemic threat, where N-Ss pose dangers and drawbacks in clinical use, and where Mantoux-type N-S ID injections are difficult to administer during mass campaigns.

NCT ID: NCT00380159 Completed - Clinical trials for Human Immunodeficiency Virus (HIV)-1 Infection

Open-Label, 48-Week Extension Study of Elvucitabine in Combination With Background Antiretroviral Therapy (ART) for Participants Who Have Completed Study ACH443-014A

Start date: September 2006
Phase: Phase 2
Study type: Interventional

To assess the safety of 48 weeks of treatment with 10 milligrams (mg) of elvucitabine in combination with background antiretroviral therapy (ART) in participants who completed Study ACH443-014A and meet the inclusion and exclusion criteria.

NCT ID: NCT00360100 Completed - Otitis Media Clinical Trials

Zmax Pediatric Vs Adult Concentration For The Treatment Of Acute Otitis Media

Start date: August 2006
Phase: Phase 3
Study type: Interventional

Assess tolerability of different dosing formulations (adult versus pediatric).

NCT ID: NCT00358943 Recruiting - Gaucher Disease Clinical Trials

International Collaborative Gaucher Group (ICGG) Gaucher Disease Registry & Pregnancy Sub-registry

Start date: April 1, 1991
Phase:
Study type: Observational [Patient Registry]

The ICGG Gaucher Registry is an ongoing, international multi-center, strictly observational program that tracks the routine clinical outcomes for patients with Gaucher disease, irrespective of treatment status. No experimental intervention is involved; patients in the Registry undergo clinical assessments and receive care as determined by the patient's treating physician. The objectives of the Registry are: - To enhance understanding of the variability, progression, identification, and natural history of Gaucher disease, with the ultimate goal of better guiding and assessing therapeutic intervention. - To assist the Gaucher medical community with the development of recommendations for monitoring patients, and to provide reports on patient outcomes, to optimize patient care. - To characterize the Gaucher disease population. - To evaluate the long-term effectiveness of imiglucerase and of eliglustat. Gaucher Pregnancy Sub-registry: The primary objective of this Sub-registry is to track pregnancy outcomes, including complications and infant growth, in all women with Gaucher disease during pregnancy, regardless of whether they receive disease-specific therapy. No experimental intervention is given; thus a patient will undergo clinical assessments and receive standard of care treatment as determined by the patient's physician.If a patient consents to this Sub-registry, information about the patient's medical and obstetric history, pregnancy, and birth will be collected, and, if a patient consents to data collection for her infant, data on infant growth through month 36 postpartum will be collected.